Biochemical control of prostate cancer with iodine-125 brachytherapy alone: experience from a single institution
- 80 Downloads
Brachytherapy is an adequate option as monotherapy for localised prostate cancer. The objective of this study was to evaluate and compare biochemical failure free survival (BFFS) after low-dose-rate brachytherapy (LDRB) alone for patients with prostate cancer using ASTRO and Phoenix criteria, and detect prognostic factors.
Data on 220 patients treated between 1998 and 2002 with LDRB were retrospectively analysed. Neoadjuvant hormone therapy was used in 74 (33.6%) patients.
Median follow-up was 53.5 months (24–116). Five year BFFS was 83.0% and 83.7% using, respectively, the ASTRO and Phoenix criteria. Low -and intermediate-risk patients presented, respectively, 86.7% and 77.8% 5-year BFFS using the ASTRO definition (p=0.069), and 88.5% and 78.6% considering the Phoenix criteria (p=0.016). Bounce was observed in 66 (30%) patients. Multivariate analysis detected PSA at diagnosis <10 ng/ml and less than 50% positive biopsy fragments as favourable prognostic factors, regarding BF using both criteria. For the Phoenix criteria, also Gleason score <7 and low-risk group were identified as independent favourable prognostic factors.
LDRB alone should be considered mostly for low-risk patients. PSA level was a strong independent prognostic factor. We support the use of the Phoenix criteria for detection of BF in patients submitted to LDRB alone.
KeywordsProstate neoplasm Biochemical failure Low dose-rate brachytherapy Radiotherapy Monotherapy
Unable to display preview. Download preview PDF.
- 2.Brasil. Ministério da Saúde. Estimativa 2010. Incidência de Câncer no Brasil. Available at www.inca.gov.br
- 5.American Society for Therapeutic Radiation Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035–1041Google Scholar
- 6.Roach M III, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRefGoogle Scholar
- 7.(2011) NCCN guidelines Version 1. Prostate Cancer. Available at www.nccn.org
- 12.Pickles T (2006) Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 64:1355–1359PubMedCrossRefGoogle Scholar
- 14.Perez CA, Michalsky JM, Lockett MA (2001) Chemical disease free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1ng/mL as end point. Int J Radiat Oncol Biol Phys 49:1287–1296PubMedCrossRefGoogle Scholar
- 22.Franca CAS, Vieira SL, Bernabe AJS, Penna ABR (2001) The seven-year preliminary results of brachytherapy with iodine-125 seeds for localized prostate cancer treated at a Brazilian single-center. Int Braz J Urol 33:752–763Google Scholar